NAVLE Gastrointestinal and Digestive

Feline Gastrointestinal Lymphoma Study Guide

📅 March 28, 2026 ⏱ 25 min read

Gastrointestinal (GI) lymphoma is the most common neoplasm in cats, accounting for 50-70% of all feline lymphoma cases and approximately 30% of all feline cancer diagnoses.

Overview and Clinical Importance

Gastrointestinal (GI) lymphoma is the most common neoplasm in cats, accounting for 50-70% of all feline lymphoma cases and approximately 30% of all feline cancer diagnoses. Following the decline of feline leukemia virus (FeLV) due to widespread vaccination, the alimentary form has become the predominant anatomical location. GI lymphoma is classified into two distinct clinical entities based on lymphocyte size: low-grade alimentary lymphoma (LGAL), also known as small cell lymphoma, and high-grade alimentary lymphoma (HGAL), also known as large cell or intermediate-to-high-grade lymphoma. This distinction is critical for the NAVLE as it directly impacts treatment selection and prognosis.

Feature	Small Cell (LGAL)	Large Cell (HGAL)
Synonyms	Low-grade, lymphocytic, well-differentiated, EATL Type II	High-grade, lymphoblastic, intermediate-grade, EATL Type I
Prevalence	60-75% of GI lymphoma	25-40% of GI lymphoma
Cell Size	Small lymphocytes (less than or equal to size of neutrophil)	Large lymphoblasts (greater than neutrophil size)
Immunophenotype	Greater than 90% T-cell (CD3+)	Variable: B-cell or T-cell
GI Location	Primarily small intestine (jejunum, duodenum)	Stomach, ileum, colon common; may form masses
Epitheliotropism	Present in 62% of cases	Present in 58% of cases
Clinical Course	Indolent, chronic (months)	Aggressive, acute (days to weeks)
Prognosis	Good: MST 2-3 years with treatment	Guarded: MST 2-9 months with treatment

Epidemiology and Risk Factors

GI lymphoma predominantly affects middle-aged to older cats with a median age of 10-13 years at diagnosis. There is no consistent breed or sex predisposition, though domestic shorthair cats are most commonly affected due to population prevalence. Unlike mediastinal or multicentric forms, alimentary lymphoma has the weakest association with FeLV antigenemia. Environmental factors, particularly secondhand tobacco smoke exposure, have been associated with a doubled risk of developing lymphoma in cats.

High-YieldLGAL (small cell) comprises 60-75% of all feline GI lymphoma cases and is increasing in incidence. Unlike HGAL, it is almost exclusively of T-cell immunophenotype and typically affects the small intestine.

Lymphoma Type	Ultrasonographic Characteristics
LGAL (Small Cell)	Diffuse circumferential thickening of muscularis propria layer Preserved wall layering (layers still distinguishable) Muscularis layer approximately twice normal thickness Muscularis-to-submucosa ratio greater than 1 (normally less than 1) Mild mesenteric lymphadenopathy May appear normal in early disease
HGAL (Large Cell)	Focal or multifocal transmural hypoechoic mass(es) Loss of normal wall layering Marked regional lymphadenopathy Wall thickness 5-25 mm May show ulceration or luminal narrowing Possible peritoneal effusion

Classification of Feline GI Lymphoma

Feature	Description
LGAL Histology	Infiltration of lamina propria by small, mature lymphocytes Epitheliotropism: lymphocytes invading intestinal epithelium forming nests and plaques Monomorphic population of small lymphocytes Widening of villi, separation of crypts May be confined to mucosa (mucosal T-cell lymphoma)
HGAL Histology	Large lymphoblasts (nuclei greater than 2x RBC size) High mitotic index Transmural infiltration through muscularis propria Complete effacement of normal architecture May show necrosis

Clinical Presentation

Small Cell Lymphoma (LGAL)

Cats with LGAL typically present with chronic, insidious clinical signs that have been present for weeks to months (median 6 months). Signs may intermittently respond to supportive medications such as antiemetics or dietary changes. Common presentations include weight loss (most consistent finding), chronic vomiting, diarrhea (small bowel or mixed), decreased or increased appetite, and lethargy. Physical examination may reveal a thin body condition score, palpably thickened intestinal loops described as having a "ropey" sensation, or may be entirely unremarkable.

Large Cell Lymphoma (HGAL)

Cats with HGAL present with acute onset of clinical signs (days to weeks) and often appear systemically unwell. Common presentations include acute vomiting and anorexia, rapid weight loss, palpable abdominal mass (most common), peritoneal effusion (in some cases), and obstruction or perforation (emergency presentation). Physical examination typically reveals an abdominal mass, hepatomegaly, or splenomegaly, and cats may show signs of dehydration or sepsis if perforation has occurred.

NAVLE TipOn the NAVLE, a chronic history of vomiting/weight loss in an older cat with diffuse intestinal thickening suggests LGAL. An acute presentation with a discrete abdominal mass suggests HGAL. The duration and pattern of clinical signs is often the most distinguishing feature between the two forms.

Drug	Dosing Protocol	Notes
Prednisolone	Initial: 2 mg/kg/day PO (5-10 mg/cat/day) Taper to: 1 mg/kg/day after 3-4 weeks Maintenance: 1 mg/kg every other day	Prednisolone preferred over prednisone in cats (more efficient hepatic conversion)
Chlorambucil	Option A: 2 mg/cat PO every 48 hrs (cats greater than 4 kg) or every 72 hrs (cats less than 4 kg) Option B (pulse): 20 mg/m2 PO every 2 weeks	Alkylating agent targeting slowly dividing lymphocytes; monitor CBC for myelosuppression
Cobalamin (B12)	250 mcg SC weekly x 6 weeks Then every 2 weeks x 6 weeks Then monthly maintenance	Supplement if hypocobalaminemic; clinical improvement may be delayed if B12 not corrected

Diagnostic Approach

Laboratory Findings

Routine bloodwork (CBC, chemistry, urinalysis) is often unremarkable or shows nonspecific changes in cats with GI lymphoma. Hypocobalaminemia (vitamin B12 deficiency) is present in up to 78% of cats with LGAL due to impaired ileal absorption. Other potential findings include mild anemia (nonregenerative), hypoalbuminemia and hypoproteinemia (more common in HGAL or advanced disease), hypocholesterolemia, elevated liver enzymes (with hepatic involvement), and elevated feline pancreas-specific lipase (f-PL). FeLV/FIV testing should be performed, though most cats with GI lymphoma are negative.

High-YieldALWAYS check serum cobalamin (B12) in cats with suspected GI lymphoma or IBD. Hypocobalaminemia is common and must be corrected for optimal treatment response. Supplementation protocol: 250 mcg SC weekly for 6 weeks, then every 2 weeks for 6 weeks, then monthly.

Ultrasonographic Findings

Abdominal ultrasound is the primary imaging modality for evaluating suspected GI lymphoma. Key findings differ between LGAL and HGAL.

Exam Focus: The classic ultrasound finding for LGAL is diffuse thickening of the MUSCULARIS PROPRIA layer with PRESERVED wall layering. For HGAL, look for a focal MASS with LOSS of wall layering. However, remember that ultrasound CANNOT reliably distinguish LGAL from IBD, as both conditions show similar muscularis thickening patterns.

Biopsy and Histopathology

Definitive diagnosis requires tissue biopsy. The gold standard is full-thickness surgical biopsy obtained via laparotomy or laparoscopy, which allows sampling of all intestinal layers and multiple GI segments. Endoscopic biopsy is less invasive but only samples the mucosa/submucosa and has lower sensitivity for detecting small cell lymphoma, which may be missed if disease is primarily in deeper layers.

Histopathologic Features

Immunohistochemistry and Clonality Testing

Immunohistochemistry (IHC) determines the immunophenotype of the lymphoid infiltrate. Key markers include: CD3 (T-cell marker), CD79a or CD20 or PAX5 (B-cell markers), and Granzyme B (cytotoxic granule marker for large granular lymphocyte lymphoma). Most LGAL cases are strongly CD3+ (T-cell), while HGAL may be B-cell or T-cell.

PCR for Antigen Receptor Rearrangement (PARR) is a clonality assay that helps distinguish neoplastic lymphoid proliferations (monoclonal) from inflammatory conditions like IBD (polyclonal). PARR targets the T-cell receptor gamma (TCRG) gene for T-cells and immunoglobulin heavy chain (IGH) gene for B-cells. It is particularly useful when histopathology is equivocal for differentiating LGAL from lymphoplasmacytic enteritis. The sensitivity is greater than 90% but specificity may be lower due to pseudoclonality. PARR should complement, not replace, histopathology and IHC.

High-YieldThe diagnostic algorithm for feline GI lymphoma is: (1) Histopathology first, (2) IHC for immunophenotyping, (3) PARR for clonality if diagnosis remains uncertain. A monoclonal T-cell population by PARR + CD3+ on IHC + consistent histology = confident diagnosis of T-cell lymphoma.

Fine Needle Aspiration Cytology

FNA cytology is more useful for diagnosing HGAL than LGAL. Cytologic features of HGAL include a monomorphic population of large lymphoblasts (larger than neutrophils), cells with high nuclear-to-cytoplasmic ratio, moderately basophilic cytoplasm with possible vacuoles, nuclei with finely stippled chromatin and visible nucleoli, and numerous mitotic figures. LGAL is rarely diagnosed by cytology alone because small, mature lymphocytes are difficult to distinguish from normal lymphoid tissue or reactive lymphadenopathy.

Protocol	Components	Response and Prognosis
CHOP (UW-25 modified)	Cyclophosphamide 200-300 mg/m2 IV Doxorubicin 1 mg/kg IV (or 20-25 mg/m2) Vincristine 0.5-0.7 mg/m2 IV Prednisolone 2 mg/kg PO daily	CR rate: 38%, PR rate: 25% Overall response: 50-75% MST: 97 days overall; greater than 1 year for cats achieving CR
COP	Cyclophosphamide 200-300 mg/m2 IV Vincristine 0.5-0.7 mg/m2 IV Prednisolone 2 mg/kg PO daily	CR rate: 30-64% MST: 4-8 months Option when doxorubicin contraindicated
Lomustine (CCNU)	50-60 mg/m2 PO every 3-4 weeks Single-agent or with prednisolone	MST: approximately 8 months for responders Option for owners preferring oral medications
Prednisolone alone	1-2 mg/kg PO daily	Palliative option MST: 2-6 weeks

Treatment Protocols

Treatment of Small Cell Lymphoma (LGAL)

LGAL is treated with oral chemotherapy at home, making it convenient for owners. The standard protocol combines prednisolone and chlorambucil.

Response and Prognosis for LGAL: Overall response rate is 85-96%, with greater than 90% of cats responding to chlorambucil/prednisolone. Median survival time is 2-3 years with treatment. Treatment is typically continued for 1 year, then discontinued if complete remission is achieved on restaging (resolution of clinical signs, normal ultrasound). Monitor with CBC every 2-3 weeks initially, then less frequently once stable.

Rescue Therapy for Relapsed LGAL

If relapse occurs after chlorambucil/prednisolone, rescue options include reintroduction of chlorambucil/prednisolone (if previously discontinued), cyclophosphamide (200-250 mg/m2 PO on days 1 and 3 every 2 weeks with prednisolone), or lomustine (CCNU). Cyclophosphamide rescue has shown 100% response rate in some studies with median second remission duration of 200+ days.

Treatment of Large Cell Lymphoma (HGAL)

HGAL requires more aggressive multi-agent chemotherapy protocols, typically CHOP-based (cyclophosphamide, doxorubicin/hydroxydaunorubicin, vincristine/Oncovin, prednisolone) or COP-based (without doxorubicin).

NAVLE TipSurgery may be indicated for HGAL if there is a discrete, resectable mass causing obstruction or perforation. Surgical debulking followed by CHOP chemotherapy has shown MST of approximately 14 months in some studies. However, surgery alone is not curative for lymphoma.

Feature	LGAL	IBD (LPE)
Lymphocyte Population	Monomorphic (uniform)	Polymorphic (mixed lymphocytes and plasma cells)
Epitheliotropism	Common: nests/plaques in epithelium	Rare to absent
PARR Clonality	Monoclonal T-cell rearrangement	Polyclonal
IHC	Predominantly CD3+ T-cells	Mixed CD3+ T-cells and CD79a+ B-cells/plasma cells

Memory Aids and Clinical Pearls

Mnemonic: "SMALL = SLOW, LARGE = LETHAL"

SMALL cell lymphoma = SLOW onset (chronic, months), SLOW progression, SIMPLE oral treatment (chlorambucil/pred), and SURVIVAL is long (2-3 years).

LARGE cell lymphoma = LETHAL if untreated, LARGE masses, LAYERS lost on ultrasound, and LIMITED survival (months).

Key Distinguishing Features

The 3 L's of LGAL: (1) Long history of chronic signs, (2) Layering preserved on ultrasound, (3) Long survival with oral chemotherapy.

The 3 M's of HGAL: (1) Mass lesion palpable/on ultrasound, (2) Multi-agent chemotherapy required (CHOP), (3) Months of survival (not years).

High-YieldRemember that approximately 10% of cats with LGAL may progress to develop HGAL as a secondary malignancy. If a cat previously treated for small cell lymphoma presents with acute decline, new mass, anemia, hypoalbuminemia, or hypoproteinemia, suspect transformation to large cell lymphoma and restage immediately.

Lymphoma Type	Treatment	Median Survival Time
LGAL (Small Cell)	Chlorambucil + Prednisolone	2-3 years (786-1078 days)
HGAL (Large Cell)	CHOP chemotherapy	6-9 months for responders; 97 days overall
HGAL with Surgery + Chemo	Surgical debulking + CHOP	Approximately 14 months
HGAL Palliative	Prednisolone alone	2-6 weeks
LGL Lymphoma	CHOP chemotherapy	Poor (weeks to months)

Differential Diagnosis: LGAL vs IBD

One of the most challenging diagnostic dilemmas in feline gastroenterology is distinguishing LGAL from inflammatory bowel disease (IBD/lymphoplasmacytic enteritis). Both conditions share similar clinical signs (chronic vomiting, weight loss, diarrhea), ultrasonographic findings (muscularis thickening), and even overlapping histologic features. Key points to remember are that IBD may precede and potentially progress to LGAL (IBD-to-lymphoma continuum), treatment for both is similar initially (prednisolone ± chlorambucil), and full-thickness surgical biopsy with IHC and PARR provides the most definitive differentiation.

Prognosis Summary

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →